[8-K/A] aTyr Pharma, Inc. Common Stock Amends Material Event Report

Rhea-AI Filing Summary

aTyr Pharma (Nasdaq: LIFE) filed Amendment No. 1 to its Form 8-K dated 7 Aug 2025 solely to correct an EDGAR header miscoding. The original report was inadvertently tagged as Item 2.06 (Material Impairments); the amendment re-submits the document under the proper Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits). All narrative content and exhibits are unchanged. Exhibit 99.1 remains the press release announcing financial results for the quarter ended 30 Jun 2025, and Exhibit 104 is the Inline XBRL cover data file. Because the earnings release is furnished—not filed—it is excluded from liability under Section 18 and from incorporation by reference unless expressly cited. No operational, financial, or strategic information has been modified; the amendment is purely administrative and carries no impact on previously disclosed results or guidance.

Insights

Securities Counsel

TL;DR—Administrative header fix; no disclosure changes.

The amendment corrects the EDGAR item code from 2.06 to 2.02, aligning the filing with its true purpose of furnishing Q2-25 results. Because no text or exhibits were altered, legal exposure and investor interpretation remain the same. The company appropriately clarifies that the furnished press release is not deemed “filed,” limiting liability under Section 18. Impact to governance and reporting integrity is neutral.

Equity Analyst

TL;DR—No change to numbers or outlook; stock impact neutral.

Investors gain no new financial information. The amendment simply retags the 8-K so screening tools correctly classify the earlier Q2 release. Valuation models and consensus estimates are unaffected. I view the event as non-impactful to the investment thesis.

false000133997000013399702025-08-072025-08-07

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

(Amendment No. 1)

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 7, 2025

ATYR PHARMA, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-37378		20-3435077
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)
10240 Sorrento Valley Road, Suite 300 San Diego, CA				92121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s telephone number, including area code: (858) 731-8389

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	ATYR	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Explanatory Note

aTyr Pharma, Inc. (the “Company”) is filing this Amendment No. 1 on Form 8-K/A (this “Amendment”) to amend its Current Report on Form 8-K furnished by the Company to the Securities and Exchange Commission (the “SEC”) on August 7, 2025 (the “Original Report”). The text of the Original Report correctly identified that it was being furnished under Item 2.02 (Results of Operations and Financial Condition) and under Item 9.01 (Financial Statements and Exhibits). However, due to administrative error, the submission header coding of the Original Report was incorrectly tagged on the SEC’s EDGAR system as Item 2.06 (Material Impairments) and Item 9.01 (Financial Statements and Exhibits). The sole purpose of this Amendment is to correct the submission header coding and re-furnish the Original Report to be tagged on the SEC’s EDGAR system as Item 2.02 (Results of Operations and Financial Condition) and under Item 9.01 (Financial Statements and Exhibits). No disclosure in the text of the Original Report, which is reproduced below in its entirety, was changed as a result of this Amendment.

Item 2.02 Results of Operations and Financial Condition.

On August 7, 2025, aTyr Pharma, Inc. issued a press release announcing financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

The information under this Item 2.02, including Exhibit 99.1 hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated August 7, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

3

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ATYR PHARMA, INC.
	By:	/s/ Jill M. Broadfoot
		Jill M. Broadfoot
		Chief Financial Officer
Date: August 7, 2025

4

FAQ

Why did aTyr Pharma (LIFE) file an 8-K/A on 7 Aug 2025?

To correct an EDGAR header error; the filing should be coded as Item 2.02, not Item 2.06.

Does the 8-K/A change aTyr Pharma's Q2 2025 financial results?

No. The amendment states that no narrative disclosures or exhibits were modified.

What exhibits are included with the amended filing?

Exhibit 99.1 is the Q2-25 earnings press release; Exhibit 104 is the Inline XBRL cover page.

Is the Q2 2025 press release considered "filed" with the SEC?

No. It is furnished under Item 2.02, so it is not subject to Section 18 liability unless later incorporated by reference.

Does the amendment signal any impairment or accounting issue at LIFE?

No. The correction removes the erroneous Item 2.06 (Material Impairments) tag, confirming no impairment disclosure.